Measuring Atopic Eczema Severity Visually
Authors:
- Carolyn R. CharmanCCCarolyn R. Charman
- Andrea J. VennAVAndrea J. Venn
- Hywel WilliamsHWHywel Williams
- Michael BigbyMBMichael Bigby
Open Access
- 1 September 2005
- journal article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 141 (9) , 1146-1151
Abstract
Measuring skin disease severity is a central part of dermatologic practice. In the outpatient clinic and in therapeutic trials it is essential to have some method of recording disease activity to ensure that health care interventions are effective. In common with many skin diseases, there are no serologic markers that accurately reflect atopic eczema severity, and, therefore, measurements are primarily based on signs and symptoms.1 Although management revolves around symptom control, traditionally greater emphasis has been placed on visual assessments of clinical signs and disease extent by physicians, especially in the clinical trial setting. In a recent review2 of 93 randomized controlled clinical trials of atopic eczema therapy published between 1994 and 2001, scoring of clinical signs was the most widely used form of outcome measure (91% of trials), with disease extent recorded in 67% of trials. Symptoms were assessed in 86% of trials but were frequently combined with clinical signs in composite scoring systems, with relatively low weighting given to patient-rated symptoms compared with physician-rated clinical signs. Furthermore, quality of life was measured in only 3% of the trials. The most widely used clinical scoring system in this review was the SCORAD (SCORing Atopic Dermatitis) index, in which 60% of the total score is based on clinical signs and 20% is based on disease extent, with only 20% weighting for patient symptoms.3-5Keywords
This publication has 14 references indexed in Scilit:
- The Patient-Oriented Eczema Measure: Development and Initial Validation of a New Tool for Measuring Atopic Eczema Severity From the Patients’ Perspective—CorrectionArchives of Dermatology, 2005
- The value of SCORAD and beyond. Towards a standardized evaluation of severity?Allergy, 2004
- Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programmeBritish Journal of Dermatology, 2004
- Measuring Atopic Dermatitis Severity in Randomized Controlled Clinical Trials: What Exactly Are We Measuring?Journal of Investigative Dermatology, 2003
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Scoring the Severity of Atopic Dermatitis: Three Item Severity Score as a Rough System for Daily Practice and as a Pre-screening Tool for StudiesActa Dermato-Venereologica, 1999
- Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic DermatitisDermatology, 1997
- Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis*British Journal of Dermatology, 1996
- Development of a symptom based outcome measure for asthmaBMJ, 1994
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994